OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Binder on Key Trials Improving the Treatment Landscape for Endometrial Cancer

November 3rd 2022

Pratibha Binder, MD, discusses key trials improving the array of treatment options for patients with endometrial cancer.

Dr. Saba on the Investigation of Pembrolizumab Plus Cabozantinib in HNSCC

November 2nd 2022

Nabil Saba, MD, FACP, discusses the evaluation of pembrolizumab plus cabozantinib in patients with recurrent metastatic head and neck squamous cell carcinoma.

Dr. Johnson on the Effect of the IPSOS Trial on Treatment in Platinum-Ineligible NSCLC

November 2nd 2022

Melissa L. Johnson, MD, discusses the paradigm-shifting results of the phase 3 IPSOS trial of atezolizumab in patients with metastatic non–small cell lung cancer.

Dr. Klempner on the Unique Trial Design of KRYSTAL-1 in CRC

November 2nd 2022

Sam Klempner, MD, discusses the design and eligibility criteria of the ongoing phase 1/2 KRYSTAL-1 trial in colorectal cancer.

Dr. Voorhees on the Utilization of Proteasome Inhibitors for Newly Diagnosed Multiple Myeloma

November 2nd 2022

Peter Voorhees, MD, discusses developments in the efficacy and application of proteasome inhibitors for patients with newly diagnosed multiple myeloma.

Dr. Goyal on the Potential Benefits of RLY-4008 in FGFR2+ Cholangiocarcinoma

November 1st 2022

Lipika Goyal, MD, discusses the potential for RLY-4008, an agent under exploration in patients with cholangiocarcinoma harboring an FGFR2 rearrangement or fusion.

Dr. Berg on the Role of the PEACE-1 and ARASENS Trials in Expanding mHSPC Treatment

November 1st 2022

Stephanie Berg, DO, discusses two key clinical trials that have advanced the standard of care in metastatic hormone-sensitive prostate cancer.

Dr. Romancik on the Phase 2 PILOT Study of Liso-Cel in Aggressive B-Cell NHL

November 1st 2022

Jason Romancik, MD, discusses the design and key results from the phase 2 PILOT study.

Dr. Salani on the Role of Molecular Profiling in Endometrial Cancer Treatment

November 1st 2022

Ritu Salani, MD, MBA, discusses the importance of histological subtyping and molecular profiling in developing treatment strategies and improving outcomes for patients with endometrial cancer.

Dr. Susanibar-Adaniya on the Evolution of Combination Therapies in Multiple Myeloma

October 31st 2022

Sandra P. Susanibar-Adaniya, MD, discusses how advancements in triplet therapy have shifted the treatment paradigm for patients with newly diagnosed, transplant-ineligible multiple myeloma.

Dr. Wee on the Current Landscape of Nonmetastatic CRPC Treatment and Classification

October 31st 2022

Christopher Wee, MD discusses the current treatment landscape for nonmetastatic castration-resistant prostate cancer, and how the success of new diagnostic tools decreases the need for this classification.

Dr. Kang on Key Results From the PALOMA-2 and PALOMA-3 Trials in Advanced Breast Cancer

October 31st 2022

Irene Morae Kang, MD, discusses key overall survival data from the phase 3 PALOMA-2 and PALOMA-3 trials, which evaluated the addition of palbociclib to standard endocrine therapy for patients with advanced breast cancer.

Dr. Dzienis on Use of Pembrolizumab with Carboplatin and Paclitaxel in HNSCC

October 31st 2022

Marcin Dzienis, MD, discusses the use of pembrolizumab with carboplatin and paclitaxel in head and neck squamous cell carcinoma .

Dr. Hamid on the Evolving Treatment of Immunotherapy in Patients With Solid Tumors

October 31st 2022

Omid Hamid, MD, discusses the evolving treatment of immunotherapy in patients with solid tumors.

Dr. Sonpavde on the Investigation of Enfortumab Vedotin Plus Pembrolizumab in Urothelial Cancer

October 31st 2022

Guru P. Sonpavde, MD, discusses the investigation of enfortumab vedotin-ejfv with or without pembrolizumab in urothelial cancer.

Women in Oncology: Leaving Passionate Legacies

October 28th 2022

Courtney DiNardo, MD, MSCE; Eunice Wang, MD; and Jessica Altman, MD, discuss the scientific achievements they have witnessed in the field of leukemia and their hopes for the future of treating this disease.

Women in Oncology: The Value of Female Leadership

October 28th 2022

Courtney DiNardo, MD, MSCE; Eunice Wang, MD; and Jessica Altman, MD, discuss how they turned career obstacles into opportunities and what they have learned from being women in the leukemia field.

Dr. Bourhis on the OS Benefit of Xevinapant Plus Chemoradiotherapy in HNSCC

October 28th 2022

Jean Bourhis, MD, PhD, discusses the overall survival benefit of xevinapant plus chemoradiotherapy in head and neck squamous cell carcinoma.

Dr. Politi on Drug-Tolerant Persister Cells in Cancer Care

October 28th 2022

Katerina Politi, PhD, discusses drug-tolerant persister cells in patients with cancer.

Dr. Gibbs on the Role of ctDNA in Predicting Distant vs Locoregional Recurrence in CRC

October 27th 2022

Peter Gibbs, MBBS, MD, FRACP, discusses the role of circulating tumor DNA in predicting distant vs locoregional recurrence in colorectal cancer.